In this video, Motley Fool health-care analyst David Williamson takes a closer look at Sarepta's (SRPT 1.72%) big move on Friday. Wall Street is starting to wake up to this small biotech story and several key catalysts in the coming months could attract even more attention.
S&P 500
5,988.56
+0.3%
+$17.75
DJI
42,468.99
+0.1%
+$41.25
NASDAQ
19,527.71
+0.3%
+$67.22
Bitcoin
105,824.00
+0.7%
+736.38
AAPL
$203.12
+0.1%
+$0.30
AMZN
$209.11
+0.9%
+$1.88
GOOG
$169.50
+1.1%
+$1.79
META
$687.21
+3.1%
+$20.36
MSFT
$464.20
+0.3%
+$1.23
NVDA
$142.89
+0.7%
+$0.97
TSLA
$321.72
-3.1%
-$10.33
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Sarepta Adds Another Supporter
By Dave Williamson
–
Jan 25, 2013 at 8:09PM
NASDAQ: SRPT
Sarepta Therapeutics
Market Cap
$4B
Today's Change
(1.72%) $0.67
Current Price
$39.54
Price as of June 4, 2025, 4:00 p.m. ET
Wall Street continues to get bullish on the small cap.
David Williamson has no position in any stocks mentioned. Follow him on Twitter @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Sarepta Therapeutics
SRPT
$39.54
(1.72%)
$0.67
GSK
GSK
$40.99
(0.47%)
$0.19
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.